lnp
(2)
Christian Cobaugh
Christian Cobaugh is a molecular biologist turned biotech operator who has spent more than 15 years at the frontier of genetic medicines. In January 2026 he became CEO of Alloy Genetic Medicines, the nucleic-acid division of Alloy Therapeutics, where he leads work on the AntiClastic cyclic nucleic acid platform for ASOs, siRNA, and other RNA therapeutics. He is best known for founding Vernal Biosciences, an mRNA contract manufacturer he built in Colchester, Vermont, on the premise that everyone who needs mRNA should be able to get it. Before Vernal he was the first scientist in the Alexion-Moderna mRNA partnership and held discovery, development, and manufacturing roles at Arcturus Therapeutics, CRISPR Therapeutics, Translate Bio, and Omega Therapeutics.
ReCode Therapeutics
ReCode Therapeutics is a clinical-stage genetic medicines company using its Selective Organ Targeting (SORT) lipid nanoparticle platform to deliver mRNA and gene-correction therapies beyond the liver. Its lead programs target cystic fibrosis and primary ciliary dyskinesia - rare respiratory diseases where existing modulators leave many patients without options.